Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta‐analysis
Cancer Medicine · 2024-09 · 13 (17)
DOI: 10.1002/cam4.70171 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Medicine, online erschienen am 10.09.2024. Verfasst von Koohyar Ahmadzadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Adenocarcinoma, Apigenin, Colorectal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iran University of Medical Sciences.
Abstract (Originalsprache)
Purpose
Therapeutic management of colorectal cancer (CRC) does not yet yield promising long‐term results. Therefore, there is a need for further investigation of possible therapeutic options. Various experiments have studied the effects of apigenin on CRC and have shown conflicting results. This systematic review and meta‐analysis investigates the currently existing evidence on the effect of apigenin on CRC.
Methods
Medline, Embase, Scopus, and Web of Science databases were searched for articles related to apigenin and its effect on CRC in the preclinical setting. Cell viability, growth inhibition, apoptosis, and cell cycle arrest for in‐vitro, and body weight, tumor size, and mortality in in‐vivo studies were extracted as outcomes.
Results
Thirty‐nine articles investigating colorectal adenocarcinoma were included in this meta‐analysis. Thirty‐seven of these studies had data for in vitro experiments, with eight studies having data for in vivo experiments. Six articles had both in vitro and in vivo assessments. Our analysis showed apigenin reduces cell viability and induces growth inhibition, apoptosis, and cell cycle arrest in in vitro studies. The few in vivo studies indicate that apigenin decreases tumor size while showing no effects on the body weight of animal colorectal adenocarcinoma models.
Conclusion
Our results demonstrated that apigenin, through reducing cell viability, inducing growth inhibition, apoptosis, and cell cycle arrest, and also by decreasing the tumor size, can be considered as a possible adjuvant agent in the management of colorectal adenocarcinoma. However, further in vivo studies are needed before any efforts to translate the current evidence into clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
- Pain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
- Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.
- Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Mahmoud Yousefifard
Förderung
- Iran University of Medical Sciences
Zitieren
APA
Ahmadzadeh, K., Roshdi Dizaji, S., Ramezani, F., Imani, F., Shamseddin, J., Sarveazad, A., & Yousefifard, M. (2024). Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta‐analysis. Cancer Medicine, 13(17). https://doi.org/10.1002/cam4.70171
Vancouver
Ahmadzadeh K, Roshdi Dizaji S, Ramezani F, Imani F, Shamseddin J, Sarveazad A, et al. Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta‐analysis. Cancer Medicine. 2024;13(17). doi:10.1002/cam4.70171
BibTeX
@article{Ahmadzadeh2024,
author = {Ahmadzadeh, Koohyar and Roshdi Dizaji, Shayan and Ramezani, Fatemeh and Imani, Farnad and Shamseddin, Jebreil and Sarveazad, Arash and Yousefifard, Mahmoud},
title = {Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta‐analysis},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {17},
doi = {10.1002/cam4.70171}
}
EUVIMED